A clinical trial of VIR-2703 (ALN-COV) for the potential treatment and/or prevention of COVID-19
Latest Information Update: 12 Aug 2020
At a glance
- Drugs VIR-2703 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 06 Aug 2020 According to an Alnylam Pharmaceuticals media release, the company plan for accelerated filing of an IND around year-end 2020.
- 08 May 2020 New trial record
- 04 May 2020 According to an Vir Biotechnology, Alnylam Pharmaceuticals Inc media release, this study is expected to begin at or around year-end 2020.